Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
BTAF1
REST API REST API
Homo sapiens
BTAF1 is differentially expressed in 233 experiments: 107 organism parts: kidney, mammary gland, ... (105 more);, 143 disease states: normal, control, ... (141 more);, 64 cell types 291 cell lines 27 compound treatments and 68 other conditions.
Synonyms TAFII170, TAF(II)170, TAF-172, TAF172, MOT1
Orthologs btaf1 (Danio rerio)   Btaf1 (Rattus norvegicus)   ENSCING00000001367 (Ciona intestinalis)   BTAF1 (Gallus gallus)   ENSCING00000014108 (Ciona intestinalis)   MOT1 (Saccharomyces cerevisiae)   Btaf1 (Mus musculus)   BTAF1 (Bos taurus)   Hel89B (Drosophila melanogaster)   ENSCING00000001362 (Ciona intestinalis)   btaf1 (Xenopus laevis)   BTAF1 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term DNA binding, negative regulation of transcription, DNA-dependent, protein binding, transcription, DNA-dependent, nucleic acid binding, ATP binding, nucleus, nucleotide binding, helicase activity, hydrolase activity, acting on acid anhydrides, sequence-specific DNA binding transcription factor activity
InterPro Term SNF2_N, HEAT, Helicase_C, DEAD-like_helicase, DUF3535
UniProt Accession Q8N6J1, Q2M1V9, B4E0W6, O14981, Q59HB6
Search EB-eye ENSG00000095564
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (22 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-18005, E-MTAB-62, ... (31 experiments)

Factor Value U/D Experiments
MCF-10A
2
E-TABM-420, E-GEOD-14990
BT20
2
E-MTAB-37, E-MTAB-62
MOLT4
2
E-MTAB-62, E-MTAB-37
PC3
1
2
E-GEOD-5258, E-GEOD-14464, E-MEXP-2034
KATOIII
1
E-MTAB-37
CA46
1
E-MTAB-37
285 more value(s).


Cell type

studied in E-GEOD-22373, E-GEOD-21668, E-GEOD-360, E-GEOD-20677, E-GEOD-4219, ... (34 experiments)

Factor Value U/D Experiments
macrophage
3
E-GEOD-360, E-GEOD-8286, E-GEOD-22373
epithelial cell
2
E-MEXP-2034, E-GEOD-10797
CD34+
2
E-AFMX-5, E-TABM-145
testis - germ cell
2
E-AFMX-5, E-TABM-145
CD8+ T cell
1
2
E-AFMX-5, E-TABM-145, E-GEOD-6740
T-ALL
1
E-GEOD-19069
58 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-MEXP-25, E-GEOD-15960, E-MEXP-2069, ... (48 experiments)

Factor Value U/D Experiments
sarcoma
2
E-MTAB-37, E-GEOD-2719
melanoma
2
E-MTAB-62, E-MTAB-37
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
prostate carcinoma
1
2
E-MTAB-62, E-GEOD-96, E-MEXP-2034
brain glioblastoma
1
E-MTAB-37
hereditary spastic paraplegia
1
E-MTAB-62
137 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-GEOD-15205, E-TABM-782, E-GEOD-3720, ... (19 experiments)

Factor Value U/D Experiments
unknown
1
E-GEOD-7307
hydrogen peroxide
1
E-GEOD-5339
control
29
1
E-GEOD-4006
granulocyte-colony stimulating factor
1
E-GEOD-7400
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
glutamine
1
E-MEXP-1335
21 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Chromosomal aberration
studied in E-TABM-125

Clinical history
studied in E-GEOD-22097, E-GEOD-19420, E-GEOD-19743, E-GEOD-7967, E-TABM-125, ... (9 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-4619, E-GEOD-21589, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

crosslinker and crosslinking wavelength
studied in E-GEOD-21918

Developmental stage
studied in E-MEXP-2359, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, E-GEOD-1751 ... (5 experiments)

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1518, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-7011, E-MEXP-1482, E-GEOD-17385, E-GEOD-20847

Genotype
studied in E-TABM-1029, E-GEOD-17476, E-TABM-868, E-GEOD-17347

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-7011, E-MEXP-1446, E-GEOD-9764, E-GEOD-10315, ... (6 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-MEXP-2069, E-TABM-15, ... (27 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-9723, E-GEOD-17400, E-GEOD-6802

Injury
studied in E-GEOD-19743

Lymph node status
studied in E-GEOD-6532

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-AFMX-1, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Phase
studied in E-GEOD-4888

Population
studied in E-MTAB-197

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-1880, E-GEOD-19445, ... (7 experiments)

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-MEXP-548, E-GEOD-3697, E-MEXP-1857 ... (5 experiments)

Sample preparation
studied in E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-7307

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-19246, E-GEOD-13818, E-GEOD-19815, E-GEOD-12198

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290

Processing time: 0.656 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM